E&C Advances QALYs Bill Despite Concerns It Could Stifle Drug Negotiation

By Gabrielle Wanneh / March 24, 2023 at 5:22 PM
The House Energy & Commerce Committee on Friday (March 24) voted to advance legislation that would ban all federal health programs from relying on research and analyses that use Quality-Adjusted Life Years (QALYs) when making coverage or pricing determinations, despite concerns by ranking Democrat Frank Pallone (NJ) that the bill could stifle Medicare drug price negotiations and prevent other comparative effectiveness research from being used to determine a drug’s value. “I need assurances that nothing in the legislation would go...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.